Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation
Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
INTRODUCTION
Disease‐modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non‐invasive blood‐based biomarker (BBBM) test for detection of amyloid‐β pathology may reduce diagnostic barriers and facilitate DMT initiation.
OBJECTIVE
To explore heterogeneity in AD care pathways and potential role of BBBM t...
Alternative Titles
Full title
Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a83a038067c846c68d79fcbef566b41b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a83a038067c846c68d79fcbef566b41b
Other Identifiers
ISSN
2352-8729
E-ISSN
2352-8729
DOI
10.1002/dad2.12508
